Zhengye Biotechnology Holding (ZYBT) Accounts Payables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Accounts Payables for 3 consecutive years, with $6.2 million the latest figure, recorded in Q4 2025.

• Quarterly Accounts Payables rose 3.75% year-over-year to $6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.2 million (up 3.75% YoY) and the FY2025 annual result came in at $6.3 million, up 6.98% from the prior year.
• Accounts Payables rose to $6.2 million in Q4 2025 per ZYBT's latest filing, from $6.0 million in the prior quarter.
• Over the last five years, Accounts Payables for ZYBT reached as high as $6.3 million in Q4 2023 and fell as low as $6.0 million in Q2 2025.
• A 3-year average of $6.1 million and a median of $6.1 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables retreated 5.69% — and 2025, when it advanced 3.75%.
• Year by year, Accounts Payables stood at $6.3 million in 2023, then dropped by 5.69% to $6.0 million in 2024, then climbed by 3.75% to $6.2 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $6.2 million, $6.0 million, and $6.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.